rare diseases
| 2 min read
The collaboration combines VRG’s AI platform with AOP Health’s expertise in rare diseases and immunology to develop a highly selective therapeutic targeting Kv1.3-mediated immune dysfunction.
| 4 min read
Real-time clinical trials, pharma deals, cancer found to be rising in young people, and more led the news this week.
| 3 min read
When science, manufacturing, and regulatory alignment move together, breakthroughs reach patients faster than ever before.
| 4 min read
Vaccination guidances, promising trial outcomes, funding bills and more led the news this week.
| 4 min read
LYMPHIR delivers targeted therapy for a rare and incurable form of skin lymphoma while opening doors for broader immuno-oncology applications.
| 4 min read
Radiprodil is in development as the first therapy designed to directly address the underlying biology of GRIN-related neurodevelopmental disorder.
| 3 min read
People with erythropoietic protoporphyria (EPP) must go to great lengths to avoid sun exposure. There have been no approved treatments that address the disease mechanism, but a new drug could change that.
| 4 min read
An FDA rejection, Takeda restructuring, Trump initiatives and more lead the news this week.
| 4 min read
AI is making studies more patient-centric, data-driven, and adaptable, ensuring patients can find, join, and stay in the trials that matter most.
| 2 min read
First DPP1 inhibitor drug milestone marks a long-awaited breakthrough for NCFB patients.
